small molecule

TPOXX

TECOVIRIMAT

Loss of exclusivityAugust 2032latest FDA-listed patent expiry
CompanySIGA TechnologiesView the full company profile on CliffBio

Drug detail

Brand nameTPOXX
Active ingredientTECOVIRIMAT
Strength200MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2018
Marketing statusRX

Listed patents

PatentExpiresType
11890270August 2032use U-2346
7737168September 2031use U-2346
9339466March 2031substance, product
12433868March 2031product
8039504July 2027product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TPOXX patent cliff — loss of exclusivity August 2032 | CliffBio